Compare AAOI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | SNDX |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2013 | 2016 |
| Metric | AAOI | SNDX |
|---|---|---|
| Price | $29.94 | $20.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $33.60 | ★ $36.92 |
| AVG Volume (30 Days) | ★ 5.1M | 2.1M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,712,000.00 | $111,304,000.00 |
| Revenue This Year | $85.86 | $620.14 |
| Revenue Next Year | $64.48 | $115.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 101.25 | ★ 595.65 |
| 52 Week Low | $9.71 | $8.58 |
| 52 Week High | $41.27 | $21.22 |
| Indicator | AAOI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 67.42 |
| Support Level | $24.83 | $20.00 |
| Resistance Level | $37.05 | $21.22 |
| Average True Range (ATR) | 2.57 | 0.93 |
| MACD | 1.02 | 0.02 |
| Stochastic Oscillator | 54.57 | 85.90 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.